December 20, 2024

Empagliflozin Reduces Risk of Diabetic Retinopathy Progression

Investigators found a 22% reduced risk of progression in patients with preexisting NPDR.

Conexiant

December 20, 2024

Workplace Discrimination in Ophthalmology

“Your husband also works, so you’re the second income.’”

Conexiant

December 18, 2024

Can Jardiance Slow Diabetic Eye Disease?

A recent report in JAMA Ophthalmology reveals that Jardiance, an oral diabetes drug, may help prevent worsening of diabetic eye disease in patients with type 2 diabetes, offering valuable insights for clinical management.

Reuters

December 16, 2024

Does Ozempic Double Eye Disease Risk?

Danish health authorities seek EU review of studies linking Novo Nordisk's Ozempic to rare eye condition in type 2 diabetes patients.

Reuters

December 10, 2024

Foveal Avascular Zone Area: A New Endpoint for Macular Capillary Nonperfusion Trials?

A subset of patients may still lose vision after PRP for diabetic retinopathy, but FAZ enlargement may be a sensitive measure for monitoring diabetic macular ischemia.

Conexiant

December 02, 2024

2024 Vitamin D Guidelines: A Critical Review

"If the pharmaceutical industry had developed a single drug capable of reducing cancer mortality by 25%, autoimmune disorders by 39%, and COVID-19 infection rates by 74%, it would be heralded as a miracle drug."

Conexiant

June 10, 2024

Melatonin May Reduce Age-related Macular Degeneration Risk

Melatonin use is associated with a reduced risk of developing and progressing age-related macular degeneration.

Conexiant

June 06, 2024

U.S. FDA Halts Biomea's Diabetes Trial

Biomea Fusion announced a clinical hold by the U.S. FDA on its diabetes drug trial due to potential toxic liver disease, causing a 60% drop in its shares.

Reuters

July 03, 2024

Semaglutide Linked to Vision-Threatening Eye Disorder

New study finds that 8.9% of type 2 diabetes patients taking semaglutide experienced NAION, compared to 1.8% of those on non-GLP-1 diabetes drugs.

Reuters